NEW YORK--(BUSINESS WIRE)--Flatiron Health is pleased to announce their presence at ISPOR—The Professional Society for Health Economics and Outcomes Research 2023 Conference, held in Boston this May. A total of ten on-stage presentations and six research posters being presented at the conference highlight how innovations in oncology real-world data (RWD) continue to advance the discipline of real-world evidence (RWE) generation.
“Flatiron’s presence at ISPOR this year includes novel machine learning models to scale evidence generation, RWD use in value assessment and market access, fit-for-purpose data quality frameworks, and research on equitable healthcare access, including diversity in clinical research,” shares Javier Jimenez, Flatiron Health Chief Medical Officer. “We’re proud to continue using data for good to impact a wider spectrum of the oncology ecosystem and are excited to share the results of our work through research and live events presented at this year’s ISPOR conference.”
Research highlights include:
- A poster presentation, included as a top 5% finalist for research presentation awards, discussing how practice level characteristics (i.e., case load, diversity, location, and clinical factors) can impact real-world overall survival among patients with multiple myeloma.
- A podium presentation discussing the impact of neighborhood structural racism on the survival outcomes of patients with metastatic breast cancer.
Schedule a meeting with Flatiron Health's RWE and Clinical Research teams at ISPOR 2023, and learn more about our abstracts and events, including workshops and panels.
Follow Flatiron Health on Twitter and LinkedIn for more updates from #ISPORAnnual and visit us in person at Booth #1135.
Poster Discussions and Presentations
Do the Characteristics of the Site of Care Influence Outcomes? Associations between Community Practice-Level Characteristics and Real-World Overall Survival Among Patients with Multiple Myeloma
Recognized as Top 5% finalist for the Research Presentation Awards
Olivier Humblet, Yihua Zhao, Ivy Altomare, Maneet Kaur, Wendy Wang, Christopher Kim, Gilis Carrigan, Michael Kelsh
Abstract: RWD51
Date: Monday, 8 May 2023
Poster session time: 3:15 - 6:45 PM
Measures of Neighborhood Structural Racism and Overall Survival Among Patients with Metastatic Breast Cancer
Podium Presentation
Harlan Pittell, Gregory S. Calip, Jenny S Guadamuz, Amy Pierre, Cleo Ryals
Abstract: P5
Date: Monday, 8 May 2023
Poster session time: 10:15 - 11:15 AM
Racialized Economic Segregation and Inequities in Survival Among Patients with Multiple Myeloma
Harlan Pittell, Jenny S Guadamuz, Maneet Kaur, Amy Pierre, Cleo Ryals, Gregory S. Calip
Abstract: HPR7
Date: Monday, 8 May 2023
Poster session time: 3:15 - 6:45 PM
Implementation of a Real-World Data Quality Framework in a Nationwide Oncology Electronic Health Record-Derived Database [Data Quality Framework]
Emily H. Castellanos, Sheenu Chandwani, Brett Wittmerhaus
Abstract: RWD96
Date: Tuesday, 9 May 2023
Poster session time: 9:45 - 1:15 PM
Assessing Missing Antineoplastic Therapy Prior to Electronic Health Record (EHR)-Derived First Line of Therapy after Advanced Non-Small Cell Lung Cancer (ANSCLC) Diagnosis
Prakirthi Yerram, Sarah D. Brake, Alemseged Ayele Asfaw, Mustafa S. Ascha, Samantha Reiss
Abstract: SA52
Date: Tuesday, 9 May 2023
Poster session time: 3:15 - 6:45 PM
Development of a Derived Induction Failure and Relapse (DIFR) Variable for Acute Myeloid Leukemia (AML) Using Real-World (RW) Data from an Electronic Health Record (EHR)-Derived Database
Christina Fullerton, Qianyi Zhang, Kelly Magee, Madeline M. Richey, Tori Williams, Doug Donnelley, Niquelle Brown-Wade, Aaron Dolor, Ahmed Sawas
Abstract: RWD158
Date: Wednesday, 10 May 2023
Poster session time: 9:00 - 11:30 AM
About Flatiron Health
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth
